# Valproate Sodium

## Depakine inj 400mg

| TAH Drug Code      | [IDEP4](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IDEP4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Epilepsy that cannot be controlled by oral routes.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Dosing             | Seizures unable to use oral form valproic acid: Total daily IV dose should be equivalent to the total daily oral valproate dose (expressed as valproic acid) and divided every 6 hours. Administer each dose as a 60-minute infusion (rate 20 mg/minute). Start intravenous administration 4 to 6 hours after the last oral administration. The original oral dose (usually an average dose of 20 to 30 mg/kg/day) can be administered by drip for 24 hours. To achieve therapeutic levels of valproic acid quickly: initially give 15 mg/kg by a slow intravenous injection (> 5 minutes)， followed by 1 mg/kg/hour intravenous continuous infusion， and adjust the dose according to target serum level and clinical symptoms.                                                                                                                                                                                                                                                                                                                               |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Contraindications  | Hypersensitivity to valproate sodium. Hepatic disease or significant hepatic dysfunction. Use in patients with mitochondrial disorders caused by mutations in mitochondrial DNA polymerase gamma (POLG; eg， Alpers-Huttenlocher syndrome) and in children younger than 2 years with a suspected POLG-related disorder. For prevention of migraine headaches in pregnant women and in women of childbearing potential who are not using effective contraception. Urea cycle disorders. Concomitant use with mefloquine or St.-John's-Wort. Patients with systemic primary carnitine deficiency whose blood levels of hypocarnitinemia have not been corrected.                                                                                                                                                                                                                                                                                                                                                                                                   |
| Adverse Effects    | Cardiovascular: Peripheral edema (3% to 8% ) Dermatologic: Alopecia (6% to 24% )， Rash (6% ) Endocrine metabolic: Increased appetite (6% )， Weight increased (4% to 9% ) Gastrointestinal: Abdominal pain (9% to 23% )， Constipation (5% )， Diarrhea (12% to 23% )， Indigestion (8% to 13% )， Loss of appetite (4% to 12% )， Nausea (22% to 48% )， Vomiting (11% to 27% ) Hematologic: Ecchymosis (4% to 5% ) Musculoskeletal: Asthenia (10% to 27% )， Backache (8% ) Neurologic: Amnesia (4% to 7% )， Ataxia (8% )， Dizziness (12% to 25% )， Headache (5% to 31% )， Insomnia (9% to 15% )， Somnolence (17% to 30% )， Tremor (9% to 57% ) Ophthalmic: Amblyopia， Blurred vision， Diplopia (16% )， Nystagmus (1% to 8% ) Otic: Tinnitus (1% to 7% ) Psychiatric: Depression (4% to 5% )， Disturbance in thinking (6% )， Feeling nervous (7% to 11% )， Mood swings (6% ) Respiratory: Bronchitis (5% )， Dyspnea (5% )， Pharyngitis (8% )， Respiratory tract infection (12% to 20% )， Rhinitis (5% ) Other: Fever (2% )， Influenza (12% ) |
| Pregnancy          | Human Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| More Info          | [UpToDate](https://www.uptodate.com/contents/valproate-valproic-acid-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

## Depakine oral solution 200mg/mL， 40mL

| TAH Drug Code      | [LDEP](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=LDEP)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Epilepsy including grand mal， petit mal， mixed and temporal lobe epilepsy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Dosing             | Giving with food to decrease gastrointestinal irritation. Children 6 years and below: syrup or oral liquid is recommended for administration. DEPAKINE 500mg Chrono Tablet is only recommended for adult and children > 17 kg. Average daily dose (per 24 hours): Adult and adolescents: 20-30 mg/kg/day in 2 or 3 divided doses. Children: 30 mg/kg/day in 2 or 3 divided doses. (< 1 year old: in 2 divided doses)                                                                                                                                                                                                                                           |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Contraindications  | Hypersensitivity to valproate sodium. Hepatic disease or significant hepatic dysfunction. Use in patients with mitochondrial disorders caused by mutations in mitochondrial DNA polymerase gamma (POLG; eg， Alpers-Huttenlocher syndrome) and in children younger than 2 years with a suspected POLG-related disorder. For prevention of migraine headaches in pregnant women and in women of childbearing potential who are not using effective contraception. Urea cycle disorders. Concomitant use with mefloquine or St.-John's-Wort. Patients with systemic primary carnitine deficiency whose blood levels of hypocarnitinemia have not been corrected. |
| Adverse Effects    | GI disturbances， ataxia， tremor， increased appetite & weight gain， edema， thrombocytopenia， inhibition of platelet aggregation; impaired hepatic function， rashes， sedation. Rarely， pancreatitis (discontinue).                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Pregnancy          | Human (and Animal) Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| More Info          | [UpToDate](https://www.uptodate.com/contents/valproate-valproic-acid-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

## Depakine 200mg

| TAH Drug Code      | [ODEP2](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ODEP2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Generalized and localized epilepsy， childhood convulsions or childhood febrile convulsions， behavioral disorders accompanied by epilepsy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Dosing             | Giving with food to decrease gastrointestinal irritation. Children 6 years and below: syrup or oral liquid is recommended for administration. DEPAKINE 500mg Chrono Tablet is only recommended for adult and children > 17 kg. Average daily dose (per 24 hours): Adult and adolescents: 20-30 mg/kg/day in 2 or 3 divided doses. Children: 30 mg/kg/day in 2 or 3 divided doses. (< 1 year old: in 2 divided doses)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Contraindications  | Hypersensitivity to valproate sodium. Hepatic disease or significant hepatic dysfunction. Use in patients with mitochondrial disorders caused by mutations in mitochondrial DNA polymerase gamma (POLG; eg， Alpers-Huttenlocher syndrome) and in children younger than 2 years with a suspected POLG-related disorder. For prevention of migraine headaches in pregnant women and in women of childbearing potential who are not using effective contraception. Urea cycle disorders. Concomitant use with mefloquine or St.-John's-Wort. Patients with systemic primary carnitine deficiency whose blood levels of hypocarnitinemia have not been corrected.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Adverse Effects    | GI disturbances， ataxia， tremor， increased appetite & weight gain， edema， thrombocytopenia， inhibition of platelet aggregation; impaired hepatic function， rashes， sedation. Rarely， pancreatitis (discontinue). Cardiovascular: Peripheral edema (3% to 8% ) Dermatologic: Alopecia (6% to 24% )， Rash (6% ) Endocrine metabolic: Increased appetite (6% )， Weight increased (4% to 9% ) Gastrointestinal: Abdominal pain (9% to 23% )， Constipation (5% )， Diarrhea (12% to 23% )， Indigestion (8% to 13% )， Loss of appetite (4% to 12% )， Nausea (22% to 48% )， Vomiting (11% to 27% ) Hematologic: Ecchymosis (4% to 5% ) Musculoskeletal: Asthenia (10% to 27% )， Backache (8% ) Neurologic: Amnesia (4% to 7% )， Ataxia (8% )， Dizziness (12% to 25% )， Headache (5% to 31% )， Insomnia (9% to 15% )， Somnolence (17% to 30% )， Tremor (9% to 57% ) Ophthalmic: Amblyopia， Blurred vision， Diplopia (16% )， Nystagmus (1% to 8% ) Otic: Tinnitus (1% to 7% ) Psychiatric: Depression (4% to 5% )， Disturbance in thinking (6% )， Feeling nervous (7% to 11% )， Mood swings (6% ) Respiratory: Bronchitis (5% )， Dyspnea (5% )， Pharyngitis (8% )， Respiratory tract infection (12% to 20% )， Rhinitis (5% ) Other: Fever (2% )， Influenza (12% ) |
| Pregnancy          | Human (and Animal) Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| More Info          | [UpToDate](https://www.uptodate.com/contents/valproate-valproic-acid-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

## DEPAKINE 500mg

| TAH Drug Code      | [ODEP5](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ODEP5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Grand mal， petit mal， mixed and temporal lobe epilepsy of epilepsy; mania.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Dosing             | Epilepsy: Adult and children > 17 kg: Initially 10-15 mg/kg/day ，then increase to the appropriate dose: 20-30 mg/kg/day in 1-2 divided doses. When epilepsy is not controlled or side effects are suspected， the blood concentration of valproic acid can be used for clinical follow-up. The effective therapeutic concentration is usually between 40-100 mg/L (280 to 700 μmol/L). Mania: Initially 600 mg daily increasing by 200 mg/day every 3 days to reach desired clinical effect. Usual dose range: 1000-2000 mg/day (20-30 mg/kg/day) Dose may be further increased to maximum 2500 mg/day if necessary.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Contraindications  | Hypersensitivity to valproate sodium. Hepatic disease or significant hepatic dysfunction. Use in patients with mitochondrial disorders caused by mutations in mitochondrial DNA polymerase gamma (POLG; eg， Alpers-Huttenlocher syndrome) and in children younger than 2 years with a suspected POLG-related disorder. For prevention of migraine headaches in pregnant women and in women of childbearing potential who are not using effective contraception. Urea cycle disorders. Concomitant use with mefloquine or St.-John's-Wort. Patients with systemic primary carnitine deficiency whose blood levels of hypocarnitinemia have not been corrected.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Adverse Effects    | GI disturbances， ataxia， tremor， increased appetite and weight gain， edema， thrombocytopenia， inhibition of platelet aggregation; impaired hepatic function， rashes， sedation. Rarely， pancreatitis (discontinue). Cardiovascular: Peripheral edema (3% to 8% ) Dermatologic: Alopecia (6% to 24% )， Rash (6% ) Endocrine metabolic: Increased appetite (6% )， Weight increased (4% to 9% ) Gastrointestinal: Abdominal pain (9% to 23% )， Constipation (5% )， Diarrhea (12% to 23% )， Indigestion (8% to 13% )， Loss of appetite (4% to 12% )， Nausea (22% to 48% )， Vomiting (11% to 27% ) Hematologic: Ecchymosis (4% to 5% ) Musculoskeletal: Asthenia (10% to 27% )， Backache (8% ) Neurologic: Amnesia (4% to 7% )， Ataxia (8% )， Dizziness (12% to 25% )， Headache (5% to 31% )， Insomnia (9% to 15% )， Somnolence (17% to 30% )， Tremor (9% to 57% ) Ophthalmic: Amblyopia， Blurred vision， Diplopia (16% )， Nystagmus (1% to 8% ) Otic: Tinnitus (1% to 7% ) Psychiatric: Depression (4% to 5% )， Disturbance in thinking (6% )， Feeling nervous (7% to 11% )， Mood swings (6% ) Respiratory: Bronchitis (5% )， Dyspnea (5% )， Pharyngitis (8% )， Respiratory tract infection (12% to 20% )， Rhinitis (5% ) Other: Fever (2% )， Influenza (12% ) |
| Pregnancy          | Human (and Animal) Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| More Info          | [UpToDate](https://www.uptodate.com/contents/valproate-valproic-acid-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

